Assessment and Treatment of Caffeine Dependence
Recent research has established that some individuals report that they are unable to cease caffeine use, despite feeling that caffeine is posing a health risk or causing significant impairment in their daily activities. Despite the high rates of unsuccessful efforts to cease or control caffeine use in the population, there has been little research on the parameters of successful caffeine reduction and no research on caffeine cessation.
The goals of the study are as follows:
- evaluate the applicability of DSM-IV dependence criteria for self-reported problematic caffeine use.
- evaluate characteristics (e.g, co-morbid psychopathology) of individuals who report that they have had difficulty quitting caffeine use on their own and who are seeking treatment for caffeine use.
- test the efficacy of a caffeine reduction treatment administered to individuals who would like to quit/reduce caffeine use, but have found it difficult to do so in the past.
|Self-identified Problematic Caffeine Use DSM-IV Substance Dependence as Applied to Caffeine||Behavioral: Individualized caffeine cessation instructions||Phase 1|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
- self-reported caffeine use [ Time Frame: as described in protocol ]
- biological measures of caffeine use [ Time Frame: as described in protocol ]
- mood questionnaires [ Time Frame: as described in protocol ]
|Study Start Date:||May 2001|
|Study Completion Date:||December 2009|
|Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
|No Intervention: Delayed intervention control||
Behavioral: Individualized caffeine cessation instructions
Intervention is described in the protocol
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00338195
|United States, Maryland|
|Behavioral Biology Research Center, Johns Hopkins Bayview|
|Baltimore, Maryland, United States, 21224|
|Principal Investigator:||Roland R Griffiths, Ph.D.||Professor, Johns Hopkins University School of Medicine|